News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

A NEW CRO LANDSCAPE

December 1, 2007

Article

The European CRO industry is becoming more competitive and complex by the day. What will it take to remain successful in this rapidly evolving landscape? Alan Morgan investigates.

Related Content

FDA Approves Rybrevant for Locally Advanced, Metastatic Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Don Tracy, Associate Editor

September 20th 2024

Article

Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer, according to Johnson & Johnson.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs

September 6th 2024

Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Aflac Launches Campaign for Bridge to Brighter

Mike Hollan

September 20th 2024

Article

The program is aimed at raising funds for children with cancer and blood disorders.

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs

August 5th 2024

Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Patritumab Deruxtecan Demonstrates Significant Survival Improvement in Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Don Tracy, Associate Editor

September 19th 2024

Article

Results of the Phase III HERTHENA-Lung02 trial demonstrated the superiority of patritumab deruxtecan over platinum plus pemetrexed induction chemotherapy in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.